On March 2, 2020, CRISPR's stock opened at a price of $54. By January 2021, amid the meme stock hype, shares of CRISPR reached highs of more than $200, and the stock was looking like a fantastic buy.

The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

In 2020, Jennifer Doudna won the Nobel Prize in chemistry for her work on the CRISPR-Cas9 gene-editing technology that allows ...

With the first medical therapy approved and systems like CRISPR-Cas showing up in complex cells, there’s a lot happening in the genome editing field. By Amber Dance/Knowable Magazine Published Jan 26, ...

LabRoots invites you to the 3rd Annual Event in the CRISPR Virtual Event Series! This event will continue the conversation of the abilities of CRISPR-based editing, next-gen editing tools, precision ...

Scientists have unveiled a new version of the famous gene-editing tool CRISPR, one that can "pause" a given gene temporarily rather than permanently turning it off. The original CRISPR system works by ...

Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition succeeded in a Phase 3 trial, a landmark for gene editing. The treatment uses Nobel Prize-winning Crispr technology ...